Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942966 | 1.00 | IDO1 (0.46) | IDO1CA12CA1CA9ALOX15 | |
| Benzamidoxime SCHEMBL4293941 | 0.80 | F2 (0.52) | HDAC1HDAC2HSD17B10GAAALDH1A1 | |
| SCHEMBL13209207 | 0.78 | GAA (0.44) | ALOX15GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL3960842 | 0.78 | GAA (0.43) | ALOX15HSD17B10GAAALDH1A1TSHR | |
| SCHEMBL3560645 | 0.78 | IDO1 (0.44) | IDO1CA12CA1CA9ALOX15 | |
| SCHEMBL12116657 | 0.78 | GAA (0.44) | ALOX15GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL3773521 | 0.78 | GAA (0.44) | ALOX15GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL6745833 | 0.78 | IDO1 (0.44) | IDO1CA12CA1CA9ALOX15 | |
| SCHEMBL18706885 | 0.78 | ALDH1A1 (0.43) | IDO1CA12CA1CA9ALOX15 | |
| SCHEMBL29899915 | 0.76 | TSHR (0.59) | HSD17B10GAAALDH1A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2987784-A1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) | 2016-02-24 | — | — | EP | disclosed |
| EP-2046732-B1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | DRITTE PATENTPORTFOLIO BETEILIGUNGS GMBH & CO KG (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8932617-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | ELFORD HOWARD L (US) | 2012-12-27 | — | — | US | disclosed |
| EP-1017353-B1 | THERAPEUTIC PROCESS FOR INHIBITING NF-KAPPA B | ELFORD HOWARD L (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8029815-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L | 2011-10-04 | — | — | US | disclosed |
| US-20090270440-A1 | BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | DRITE PATENTPORTFOLIO BETEILLIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-2046732-A1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co.KG (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | ELFORD HOWARD L | 2008-02-28 | — | — | US | disclosed |
| WO-2008009264-A1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2008-01-24 | — | — | WO | disclosed |
| US-6924308-B1 | Therapeutic process for inhibiting NF-κB | MOLECULES FOR HEALTH, INC. | 2005-08-02 | — | — | US | disclosed |
| EP-0610444-B1 | Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases | ELFORD HOWARD L (US) | 2003-01-29 | — | — | EP | disclosed |
| US-5350770-A | Administering hydroxy benzamide derivative | ELFORD HOWARD L (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1994002135-A1 | THERAPEUTIC PROCESS FOR THE TREATMENT OF SEPTIC SHOCK | ELFORD HOWARD L (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | IDO1 606/4885CA12 4523/4885CA1 2703/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | IDO1 606/4885CA12 4523/4885CA1 2703/4885 |
| US-20090270440-A1 | BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | HNMT, SLC7A1, HRH4 | IDO1 228/4885CA12 3982/4885CA1 2991/4885 |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | IDO1 3673/4885CA12 4319/4885CA1 4730/4885 |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | IDO1 3673/4885CA12 4319/4885CA1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.